BioLineRx Announces Receipt of Notice of Allowance from USPTO for Patent Covering BCM

BioLineRx BLRX announced today that a Notice of Allowance has been issued by the United States Patent and Trademark Office for a patent application claiming the composition of BL-1040, a novel medical device for prevention of cardiac remodeling following an acute myocardial infarction. This patent, when issued, will be valid until August 2026. Additional patents claiming the BL-1040 composition and its use for the treatment of ventricular remodeling and congestive heart failure due to acute myocardial infarction are granted or pending in Europe, Japan, Canada, Korea, Mexico, Israel, India, China and Australia.